{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T09:43:36.314512+00:00","company":{"ticker":"TLPH","cik":1427925,"company_name":"TALPHERA, INC."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"7fc29ab8965365a07c6ae241cc8d669da7227cd9","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2026-03-13T23:59:59+00:00","payload":{"company_response":"intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance","compliance_status":"deficient","cure_deadline":"2026-09-07","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2026-03-11","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"TALPHERA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"March 11, 2026, Talphera, Inc., (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a p","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-008217","anchor_url":"https://secwatch.observer/filing/0001437749-26-008217#claim-7fc29ab8965365a07c6ae241cc8d669da7227cd9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926008217/0001437749-26-008217-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"085fe69ed06da66e4708320913ea5a18dfb30c54","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2025-06-05T23:59:59+00:00","payload":{"company_response":"intends to monitor and consider available options","compliance_status":"extension_granted","cure_deadline":"2025-12-01","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-06-05","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5450(a)(1)","5810(c)(3)(A)","5810(c)(3)(A)(ii)"],"rules_cited_in_text":true},"claim":"TALPHERA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(A)(ii)).","evidence_excerpt":"June 5, 2025, Talphera, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) granting the Company an additional 180 days, until December 1, 2025 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. As previously announced, on December","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-019574","anchor_url":"https://secwatch.observer/filing/0001437749-25-019574#claim-085fe69ed06da66e4708320913ea5a18dfb30c54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925019574/0001437749-25-019574-index.htm"},{"fact_type":"executive_change","fact_key":"b11649b19d","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-08-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Shakil Aslam was appointed as Chief Medical Officer at TALPHERA, INC..","evidence_excerpt":"Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-026815","anchor_url":"https://secwatch.observer/filing/0001437749-24-026815#claim-b11649b19d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm"},{"fact_type":"executive_change","fact_key":"f97f5f84eb","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-08-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"retirement","effective_date":"2024-10-01","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":"Shakil Aslam","successor_named":true},"claim":"Pamela P. Palmer resigned as Chief Medical Officer at TALPHERA, INC..","evidence_excerpt":"On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-026815","anchor_url":"https://secwatch.observer/filing/0001437749-24-026815#claim-f97f5f84eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm"},{"fact_type":"earnings_release","fact_key":"425dbbb79d1fe7380bc6464c7c2d364e6d8e6a4a","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$0.16 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.0 million","period_text":"the three months ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"TALPHERA, INC. reported the three months ended March 31, 2024 results: net income $4.0 million, EPS $0.16 per basic and diluted share.","evidence_excerpt":"Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-016626","anchor_url":"https://secwatch.observer/filing/0001437749-24-016626#claim-425dbbb79d1fe7380bc6464c7c2d364e6d8e6a4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/0001437749-24-016626-index.htm"},{"fact_type":"earnings_release","fact_key":"b9a55aeeb362c5f09a10e256f73785bf23ebe9d9","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":"$0.25 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.5 million","period_text":"the three months ended December 31, 2023","report_date":"2024-03-06","result_type":"reported_results","revenue_text":"$0.3 million"},"claim":"TALPHERA, INC. reported the three months ended December 31, 2023 results: revenue $0.3 million, net income $4.5 million, EPS $0.25 per basic and diluted share.","evidence_excerpt":"● The cash and cash equivalents balance was $9.4 million as of December 31, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.3 million for the fourth quarter primarily represent the revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the prior","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-006817","anchor_url":"https://secwatch.observer/filing/0001437749-24-006817#claim-b9a55aeeb362c5f09a10e256f73785bf23ebe9d9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm"},{"fact_type":"executive_change","fact_key":"d20b51f05a","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Pamela P. Palmer, M.D., Ph.D. resigned as Director at TALPHERA, INC..","evidence_excerpt":"On February 28, 2024, Pamela P. Palmer, M.D., Ph.D. resigned as a member of the Company's board of directors effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-006219","anchor_url":"https://secwatch.observer/filing/0001437749-24-006219#claim-d20b51f05a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006219/0001437749-24-006219-index.htm"},{"fact_type":"executive_change","fact_key":"a2eb5776ee","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Howard B. Rosen resigned as Director at TALPHERA, INC..","evidence_excerpt":"On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the \"Company\"), and any and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-006219","anchor_url":"https://secwatch.observer/filing/0001437749-24-006219#claim-a2eb5776ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006219/0001437749-24-006219-index.htm"},{"fact_type":"executive_change","fact_key":"c897e8e916","cik":1427925,"ticker":"TLPH","company_name":"TALPHERA, INC.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard Afable, M.D. resigned as Director at TALPHERA, INC..","evidence_excerpt":"On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the \"Company\"), and any and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-006219","anchor_url":"https://secwatch.observer/filing/0001437749-24-006219#claim-c897e8e916","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006219/0001437749-24-006219-index.htm"}]}